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Abstract
Wiskott-Aldrich syndrome is a rare X-linked immunodeficiency disorder that is characterized by a variable clinical
phenotype. Matched donor bone marrow transplantation is currently the only curative therapeutic option. We
present the case of a 24-year-old male who was diagnosed at the age of seven with Wiskott-Aldrich syndrome. He
did not respond to intravenous gammaglobulin and he experienced recurrent pulmonary infections despite
prophylactic antibiotics. The patient had no matched donor. At the age of nine, he was submitted to splenectomy
and his platelet count was normalized. Fifteen years later, the patient remains asymptomatic with a normal platelet
count. He is still receiving prophylactic antibiotics and no bleeding episodes or septic complications have been
reported. This case demonstrates that splenectomy can represent a safe therapeutic option in selected WAS
patients, provided that there is a tight follow-up program, patient education and adherence to guidelines
regarding post-splenectomy prophylaxis.
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Background
Wiskott-Aldrich syndrome (WAS) is a rare immunodefi-
ciency disorder, which is characterized by recurrent
infections, small-platelet thrombocytopenia and eczema.
It has been associated with increased risk of autoimmune
disorders and malignancy [1]. The syndrome was first
described in 1937 by Wiskott in three brothers with con-
genital thrombocytopenia, eczema, bloody diarrhea and
multiple ear infections [2], whereas, in 1954, Aldrich
reported that this disorder is associated with X-linked
inheritance [3]. WAS has a wide range of clinical pheno-
types that correlate with the type of mutation in the
WASP gene. The three main clinical phenotypes pro-
duced by WASP mutations are classic WAS, X-linked
thrombocytopenia and X-linked neutropenia [4]. Clinical
manifestations of WAS consist of petechiae, ecchymosis
and bloody diarrhea [1]. Recurrent infections are a fre-
quent problem and autoimmune diseases further compli-
cate clinical presentation [4]. Treatment is mainly
supportive and includes immunization, intravenous
gammaglobulin, corticosteroids, transfusions, prophylac-
tic antibiotics and splenectomy [5]. Matched bone
marrow transplant seems to be t h eo n l yc u r a t i v et h e r a -
peutic option [6], whereas gene therapy holds much pro-
mise for future use in clinical practice [7]. When a
matched donor is not available, the number of treatment
options available is small and overall prognosis is poor
[6].
Splenectomy is used sparingly by WAS treatment cen-
ters, mainly because of the potential post-splenectomy
complications [8]. We present the case of a patient with
WAS with prolonged survival after splenectomy, who is
on a tight follow-up program and tightly adheres to the
prophylactic regimen. No sign of disease recurrence has
been reported nor has any serious complication.
Case presentation
Case report
Our patient first presented at our department at the age
of seven with facial eczema, recurrent pulmonary infec-
tions (lasting several weeks) and otitis media. Physical
examination revealed a severe eczema and laboratory
tests showed microcytic thrombocytopenia with a plate-
let count of 42000/mL at diagnosis. His white blood cell
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Bone marrow biopsy ruled out aplastic anemia. He had
a low IgG (495 mg/dl, normal levels > 560 mg/dl for
age) and IgM (95 mg/dl, normal levels > 145 mg/dl for
age) count and elevated IgA (270 mg/dl, normal levels
< 250 mg/dl for age) and IgE levels (1680 IU/ml, normal
levels < 420 IU/ml for age). Coagulation tests were nor-
mal as were the total count and morphology of mega-
caryocytes. He had no known family history of the
disease but a maternal uncle was reported to have died
in childhood after experiencing similar symptoms. The
patient received multiple courses of intravenous gamma-
globulin, steroids, transfusions and prophylactic antibio-
tics. His thrombocytopenia was refractory (platelet
count ranging from 8000-78000/mL) and he experienced
multiple bleeding episodes. At the age of eight, he also
exhibited autoimmune Henoch-Schönlein-like purpura
and lymphopenia of variable severity. The patient had
neither a matched-donor sibling nor a matched unre-
l a t e dd o n o r .A tt h ea g eo fn i n e ,t h ep a t i e n tu n d e r w e n t
splenectomy. His platelet count was normalized has been
normal ever since with a mean value of 235000/mL.
T h e r eh a v eb e e nn os i g n so fd i s e a s er e c u r r e n c ei nt h e
last fifteen years or any autoimmune manifestations of
WAS. Levels of immunoglobulins are within normal
limits and the eczema has not reappeared. The patient
w a se d u c a t e df r o mav e r yy o u n ga g ea b o u tt h ei m p o r -
t a n c eo ft a k i n gs p e c i f i cp o s t - s p l e n e c t o m yp r e v e n t i v e
measures: Vaccination for pneumonococcus, haemophi-
lus influenza B and meningococcal C pathogens is con-
ducted according to guidelines and antibody levels are
measured to make sure that response is adequate. The
patient is currently on life-long phenoxymethylpenicillin
250 mg per os twice daily. All post-splenectomy febrile
illnesses of the patient are carefully evaluated and com-
plete blood work is performed to rule out sepsis. Antibio-
tic sensitivity testing on isolated pathogens is performed.
A mutation analysis was conducted six years ago and a
missence mutation in the exon 2 of the patient’sW A S P
gene was detected. Furthermore, the patient lacked
WASP protein expression. He has experienced no epi-
sodes of post-splenectomy bleeding or sepsis. His compli-
ance with the recommended treatment has always been
exceptional.
Discussion
WAS is a multifaceted syndrome which is characterized by
sinopulmonary infections, microthrombocytopenia and
eczema [1]. The vast majority of patients have episodes of
bleeding, which are life-threatening in a percentage reach-
ing 30% [9]. According to the Zhu classification (1997)
[10], our patient is classified as score 4 WAS, due to
severe, treatment-resistant eczema, recurrent infections
and presence of autoimmune disease (Henoch-Schönlein-
like purpura). He also lacked WASP protein expression,
which can be rarely observed in missence patients [11].
However, it should be noted that missence mutations to
exons 1-3 have been associated with milder phenotypes
[10] and positive WASP expression [11].
The mutations responsible occur in the WAS gene, that
regulates actin polymerization in hematopoietic cells.
Thrombocytopenia in this syndrome seems to be attribu-
ted to increased phagocytosis and spleen destruction as
well as ineffective thrombocytopoiesis. Patients with WAS
have combined immunodeficiency, as functions of T and
B lymphocytes and NK cells are affected [4]. Main causes
of death are severe bleeding episodes, infections, autoim-
mune diseases and hematological malignancies [1].
Currently, the only curative therapy for WAS is hemato-
poietic stem cell transplantation (HSCT) [6], whereas gene
therapy is still under study [7]. Matched unrelated donors
can also be used for HSCT in WAS patients. A 2006
Japanese study showed that the overall 5-year survival rate
is 80% for WAS patients treated with HSCT from matched
unrelated donors or unrelated cord blood [12], while an
Italian single-center trial concluded that survival rates
were even better (81.2%) in case of unrelated donors [13].
Transplant is, however, associated with significant risk of
morbidity and mortality and this should be taken into
account, especially in patients with some other phenotype
variant and not classic WAS [6]. In patients with no avail-
able matched donor or ineligible because of age, treatment
is mainly supportive with intravenous gammaglobulin,
prophylactic antibiotics and immunization. Systemic ster-
oids generally fail to improve thrombocytopenia and
immunocompromise the patient even further. The out-
come is usually poor in these patients with only few of
them surviving into adulthood [8].
Splenectomy is one of the treatment options available
in patients who are not submitted to transplantation but
it is used sparingly by centers worldwide, since it carries
significant risk of severe infections and sepsis [8]. Conley
et al [8] in 2003 reported that less than 10% of treatment
centers use splenectomy systematically as a treatment
option whereas, 26.3% never select this modality. It has
been shown to be an effective measure to sustain an
increase in platelet counts [14]. The exact mechanism of
action is not known, however, it is believed that platelet
destruction is decreased and that blocking of this clear-
ance mechanism assists in offsetting impaired platelet
production [15]. The main concern regarding the wider
use of splenectomy is the post-splenectomy bleeding and
sepsis [14]. The Mullen et al study [14] showed that
recurrence of bleeding was mainly reported in patients
who developed idiopathic thrombopenic purpura (ITP)
and that half of these patients had already been diag-
nosed with ITP before splenectomy. A recent multicenter
study conducted in a large cohort of XLT patients
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bleeding events is not significantly reduced after sple-
nectomy [5]. Regarding post-splenectomy sepsis, more
than half of the patients were not receiving the recom-
mended prophylactic antibiotics or had discontinued the
regimen [14]. According to Albert et al [16], despite the
higher risk for systemic infections after splenectomy,
antibiotic prophylaxis and vaccination may render sple-
nectomy a reasonable treatment of choice for some XLT
patients, provided that the family situation and compli-
ance issued are taken into careful account.
Our case confirms that prolonged survival can be
achieved post-splenectomy in patients with WAS, given
that there is a systematic approach in their post-splenect-
omy medical care. Contrary to historical experience,
this patient experienced prolonged normalization of his
platelet count after splenectomy. Increased survival after
splenectomy has been previously reported but we propose
a cautious and systematic post-operative surveillance
which seems to improve the outcome. The patient had
been very carefully educated regarding the importance of
complying with the preventive regimen and of informing
all treating physicians about his being asplenic before
receiving any treatment. A careful and sensitive approach
helped avoid compliance issues in adolescence as well,
which has been recognized as a period of increased risk of
treatment refusal [16]. The guidelines for prevention and
treatment of infections in patients with absent or dysfunc-
tional spleen were followed, as have been published and
revised by the British Committee for Standards in Hema-
tology [17]. Furthermore, the patient received the recom-
mended immunization for splenectomized patients and
the adequate response to the vaccination was monitored
by regularly measuring antibody levels. It should be noted
that the patient produces anti-polysaccharide antibodies at
levels within normal range, even though a defective WAS
gene has been detected. Improvement in cellular immunity
has been described after splenectomy in WAS since 1981
[18] and this could be associated with the adequate
response to vaccination observed in our case. Post-
splenectomy, he did not experience increased infectious
complication while on prophylactic antibiotics and routine
vaccinations. Fifteen years after splenectomy, he continues
to function as an energetic youth without complications.
The appropriate timing of splenectomy and selection of
candidates are matters for discussion. With the emergence
of antibiotic resistant strains of pneumonococcus, it is
possible that regular infusions of IVIG are also needed as
prophylaxis in cases of patients who do not adequately
respond to vaccination.
Conclusions
In conclusion, prolonged survival with no thrombocyto-
penia recurrence can be achieved in WAS patients who
undergo splenectomy, without any grave complications,
with a focus on post-splenectomy patient care and
compliance.
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